Loading patent…
AssigneeSedogen LLC
InventorSara P. Cotter
Estimating the term…
This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.
A method of treating a Prader-Willi Syndrome (PWS) patient that exhibits-one or more behavioral symptoms of a PWS nutritional phase comprising managing the PWS patient with a diet having restricted or reduced caloric intake compared to the recommended daily allowance (RDA), and administering to the PWS patient diazoxide or a salt thereof in an amount effective to reduce one or more behavioral symptoms, wherein the PWS patient is in nutritional phase 1a, 1b, 2a, 2b, or 3.
A method of treating a Prader-Willi Syndrome (PWS) patient that exhibits one or more food-related behavioral symptoms of a PWS nutritional phase, comprising managing the PWS patient with a diet having restricted or reduced caloric intake compared to the recommended daily allowance (RDA), and administering to the patient diazoxide or a salt thereof in an amount effective to reduce the one or more food-related behavioral symptoms.
A method of treating a Prader-Willi Syndrome (PWS) patient that exhibits one or more food-related behavioral symptoms of a PWS nutritional phase, comprising managing the PWS patient with a diet having restricted or reduced caloric intake compared to the recommended daily allowance (RDA), and administering to the patient diazoxide or a salt thereof in an amount effective to reduce the one or more food-related behavioral symptoms, and wherein the PWS patient is in nutritional phase 1a, 1b, 2a, 2b, or 3.
Dependencies are inferred from the claim text.